In 2003, Scott Rocklage joined 5AM Venture as a committed venture partner. In 2004, he was appointed to serve as a managing partner. For over three decades, Scott Rocklage has gained extensive experience in healthcare management. At Cubist Pharmaceuticals, Scott served as the CEO and chairman of the board. In addition, he served as the chief executive officer of Nycomed Salutar. At Salutar and Catalytica Scott worked in the R$D department.
At Novira and Relypsa organizations, Scott played an integral role of chairing board meetings, thus the success of these corporations. Presently, Scott manages Rennovia, Cidara (NASDAQ: CDTX) and Kinestral as the chairperson of the board. Moreover, he is the chairman of other renowned and successful companies, Pulmatrix (NASDAQ: PULM) and Epirus (NASDAQ: EPRS). Through his visionary leadership, he has been able to facilitate the approval of new drugs by the FDA. After successful clinical trials, Scott has been able to patent six of his ideas and contact him.
Formerly, Scott served as the executive chairperson of llypsa, Miikana and Semprus. Scott is an alumnus of the University of California, Berkeley, where he graduated with a bachelor’s degree in chemistry. Later, he joined the MIT where he earned his PhD in chemistry. While he was a student at the prestigious MIT, Rocklage undertook research at Richard R. Schrock laboratory. He owns over 30 U.S. patents for different products and ideas that he has invented or co-invented. Scott has written more than 100 peer-reviewed journals. He resides in Boston.
Rocklage considers his company, 5AM Ventures, to be at the early stages of its life cycle. However, he is optimistic that the corporation is in a growth trajectory. Scott admits that he does not have a typical day and read full article.
Scott makes his day productive by attending various board meetings, organizing different activities, researching on various topics on life science and coordinating activities in his company. In addition, the executive works closely with entrepreneurs, different heads of businesses, physicians and scientists in sharpening their strategies. To this end, he gains new ideas. Scott believes that he has managed to be a prudent entrepreneur because of focusing on strategic planning, calendaring and managing his time. Over the years, the investor has been taking risks. He posits that it is through such bold moves that investors can be able to realize better returns from their portfolios and what Scott knows.